These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11334309)

  • 21. Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.
    Costa-de-Oliveira S; Miranda IM; Silva-Dias A; Silva AP; Rodrigues AG; Pina-Vaz C
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4289-92. PubMed ID: 25845879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New molecular methods to study gene functions in Candida infections.
    Theiss S; Köhler GA; Kretschmar M; Nichterlein T; Hacker J
    Mycoses; 2002 Nov; 45(9-10):345-50. PubMed ID: 12421279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pga26 mediates filamentation and biofilm formation and is required for virulence in Candida albicans.
    Laforet L; Moreno I; Sánchez-Fresneda R; Martínez-Esparza M; Martínez JP; Argüelles JC; de Groot PW; Valentín-Gomez E
    FEMS Yeast Res; 2011 Aug; 11(5):389-97. PubMed ID: 21439008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of filamentation can be used to treat disseminated candidiasis.
    Saville SP; Lazzell AL; Bryant AP; Fretzen A; Monreal A; Solberg EO; Monteagudo C; Lopez-Ribot JL; Milne GT
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3312-6. PubMed ID: 17005810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A system for studying genetic changes in Candida albicans during infection.
    Forche A; May G; Beckerman J; Kauffman S; Becker J; Magee PT
    Fungal Genet Biol; 2003 Jun; 39(1):38-50. PubMed ID: 12742062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular characterization of fluconazole resistance in a case of Candida albicans ocular infection.
    Pancholi P; Park S; Perlin D; Kubin C; Della-Latta P
    J Clin Microbiol; 2004 Dec; 42(12):5938-9. PubMed ID: 15583347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in molecular genetics of Candida albicans and Candida glabrata.
    Brown AJ; Cormack BP; Gow NA; Kvaal C; Soll DR; Srikantha T
    Med Mycol; 1998; 36 Suppl 1():230-7. PubMed ID: 9988512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the CaNAG3, CaNAG4, and CaNAG6 genes of the pathogenic fungus Candida albicans: possible involvement of these genes in the susceptibilities of cytotoxic agents.
    Yamada-Okabe T; Yamada-Okabe H
    FEMS Microbiol Lett; 2002 Jun; 212(1):15-21. PubMed ID: 12076781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there any relationship between fluconazole resistance and some virulence factors in Candida albicans strains?
    Ozkütük A; Ergon C; Ozdemir S; Yulug N
    J Chemother; 2003 Dec; 15(6):616-7. PubMed ID: 14998091
    [No Abstract]   [Full Text] [Related]  

  • 30. Candida albicans morphology: still in focus.
    Jacobsen ID; Hube B
    Expert Rev Anti Infect Ther; 2017 Apr; 15(4):327-330. PubMed ID: 28152317
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeting the fungal calcium-calcineurin signaling network in overcoming drug resistance.
    Li X; Sun S
    Future Med Chem; 2016 Aug; 8(12):1379-81. PubMed ID: 27463738
    [No Abstract]   [Full Text] [Related]  

  • 32. Candida albicans: fundamental research on an opportunistic human pathogen.
    Calderone R; Odds FC; Boekhout T
    FEMS Yeast Res; 2009 Oct; 9(7):971-2. PubMed ID: 19845040
    [No Abstract]   [Full Text] [Related]  

  • 33. Betamethasone augments the antifungal effect of menadione--towards a novel anti-Candida albicans combination therapy.
    Jakab Á; Emri T; Sipos L; Kiss Á; Kovács R; Dombrádi V; Kemény-Beke Á; Balla J; Majoros L; Pócsi I
    J Basic Microbiol; 2015 Aug; 55(8):973-81. PubMed ID: 25707543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifungal susceptibility of Candida albicans in biofilms.
    Tobudic S; Kratzer C; Lassnigg A; Presterl E
    Mycoses; 2012 May; 55(3):199-204. PubMed ID: 21793943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virulence genes in the pathogenic yeast Candida albicans.
    Navarro-García F; Sánchez M; Nombela C; Pla J
    FEMS Microbiol Rev; 2001 Apr; 25(2):245-68. PubMed ID: 11250036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fungal endophthalmitis.
    Chhablani J
    Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1191-201. PubMed ID: 22114969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans.
    Angiolella L; Stringaro AR; De Bernardis F; Posteraro B; Bonito M; Toccacieli L; Torosantucci A; Colone M; Sanguinetti M; Cassone A; Palamara AT
    Antimicrob Agents Chemother; 2008 Mar; 52(3):927-36. PubMed ID: 18180350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity of White and Opaque Candida albicans Cells to Antifungal Drugs.
    Craik VB; Johnson AD; Lohse MB
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis of Candida albicans biofilm.
    Tsui C; Kong EF; Jabra-Rizk MA
    Pathog Dis; 2016 Jun; 74(4):ftw018. PubMed ID: 26960943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein kinases as potential anticandidal drug targets.
    Singh S; Rehman S; Fatima Z; Hameed S
    Front Biosci (Landmark Ed); 2020 Mar; 25(8):1412-1432. PubMed ID: 32114439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.